Free Trial
NASDAQ:APLT

Applied Therapeutics Q1 2024 Earnings Report

Applied Therapeutics logo
$0.43 -0.01 (-2.36%)
Closing price 09/19/2025 04:00 PM Eastern
Extended Trading
$0.44 +0.01 (+2.37%)
As of 09/19/2025 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Applied Therapeutics EPS Results

Actual EPS
-$0.16
Consensus EPS
-$0.07
Beat/Miss
Missed by -$0.09
One Year Ago EPS
N/A

Applied Therapeutics Revenue Results

Actual Revenue
$0.19 million
Expected Revenue
$10.00 million
Beat/Miss
Missed by -$9.81 million
YoY Revenue Growth
N/A

Applied Therapeutics Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Thursday, May 9, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Applied Therapeutics' Q3 2025 earnings is scheduled for Thursday, November 6, 2025, with a conference call scheduled on Monday, November 10, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Applied Therapeutics Earnings Headlines

Applied Therapeutics Reports Q2 Loss
This is the “End of Tesla” as we know it…
Jeff has identified five of the past seven number-one performing tech stocks — before they took off. His Tesla call alone could have made readers 21 TIMES THEIR MONEY, if they listened to his recommendation. Don't miss his next big prediction.tc pixel
Applied Therapeutics, Inc. (APLT) - Yahoo Finance
See More Applied Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Applied Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Applied Therapeutics and other key companies, straight to your email.

About Applied Therapeutics

Applied Therapeutics (NASDAQ:APLT), Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel small-molecule therapies for genetically defined diseases. Its research strategy centers on structure-based drug design and proprietary screening technologies aimed at correcting underlying metabolic dysfunction in disorders characterized by enzyme deficiencies and toxic metabolite accumulation.

The company’s lead investigational candidate, AT-007, is an aldose reductase inhibitor engineered to cross the blood–brain barrier and is currently in clinical development for classic galactosemia. In addition to AT-007, Applied Therapeutics is advancing multiple programs targeting rare neurological and endocrine disorders, leveraging its platform to identify and optimize compounds that address high unmet medical needs in orphan and genetically defined patient populations.

Founded and headquartered in New York City, Applied Therapeutics has established collaborative partnerships with academic research institutions and contract research organizations throughout North America and Europe to support its preclinical and clinical operations. The company is guided by a leadership team with extensive experience in drug discovery, clinical development and regulatory affairs, positioning Applied Therapeutics to advance its pipeline toward key clinical milestones and potential regulatory approval.

View Applied Therapeutics Profile

More Earnings Resources from MarketBeat